A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall

• Published in: Journal of vascular surgery 2002-07, Vol.36 (1), p.158-163
• Main Authors: Nagashima, Hirotaka, Aoka, Yoshikazu, Sakomura, Yasunari, Sakuta, Akiko, Aomi, Shigeyuki, Ishizuka, Naoko, Hagiwara, Nobuhisa, Kawana, Masatoshi, Kasanuki, Hiroshi
• Format: Article
• Language: English
• Subjects: Aorta, Abdominal - cytology; Aorta, Abdominal - metabolism; Aortic Aneurysm, Abdominal - drug therapy; Aortic Aneurysm, Abdominal - metabolism; Apoptosis - drug effects; Biological and medical sciences; Dose-Response Relationship, Drug; Drug Evaluation; General and cellular metabolism. Vitamins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Immunohistochemistry; Japan; Matrix Metalloproteinase 9 - biosynthesis; Matrix Metalloproteinase 9 - drug effects; Medical sciences; Muscle, Smooth, Vascular - cytology; Muscle, Smooth, Vascular - drug effects; Pharmacology. Drug treatments; Pyridines - administration & dosage; Treatment Outcome
• ISSN: 0741-5214; 1097-6809
• DOI: 10.1067/mva.2002.123680

Aim: Abdominal aortic aneurysm (AAA) is a common vascular degenerative disease. AAA wall contains inflammatory cells that produce matrix metalloproteinases (MMPs) that probably contribute to elastolysis and remodeling of the aneurysm. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to reduce the expression of various molecules (including MMPs) independently of their cholesterol-lowering effect. The aims of this study are to investigate whether statins could modulate the biology of AAA wall and have a potential therapeutic value against AAAs. Methods: We performed immunohistochemical analysis, evaluated MMP-9 production in the aortic wall from patients with infrarenal AAA (n = 10) and control patients with aortoiliac occlusive disease (n = 8), and examined the effect of cerivastatin on MMP-9 production in the AAA wall with organ culture. Results: Neutrophils and macrophages were the cellular sources of MMP-9 in the AAA wall. The tissue concentrations of both total and active MMP-9 were significantly higher in tissues from AAA walls than in control aortic walls. Cerivastatin (0.001 to 0.1 μmol/L) significantly reduced the tissue levels of both total and active MMP-9 in a concentration-dependent manner ( P < .001), and the production of tissue inhibitor of MMP-1 was unaffected. Cerivastatin neither reduced the number of infiltrating neutrophils and macrophages nor enhanced apoptosis of those cells, as evaluated with terminal transferase-mediated deoxyurisine triphosphate nick end labeling. Conclusion: These results suggest that cerivastatin can directly modulate the biology of the AAA wall and suppress MMP-9 production in the AAA wall by inhibiting the activation of neutrophils and macrophages, indicating that statin therapy could be useful for the prevention or treatment of AAA. (J Vasc Surg 2002;36:158-63.)